Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort

OBJECTIVE: To assess disease activity within 12 months after natalizumab (NZ) discontinuation in a large French postmarketing cohort. METHODS: In France, patients exposed at least once to NZ were included in the TYSEDMUS observational and multicenter cohort, part of the French NZ Risk Management Pla...

Descripción completa

Detalles Bibliográficos
Autores principales: Papeix, Caroline, Vukusic, Sandra, Casey, Romain, Debard, Nadine, Stankoff, Bruno, Mrejen, Serge, Uhry, Zoe, Van Ganse, Eric, Castot, Anne, Clanet, Michel, Lubetzki, Catherine, Confavreux, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087255/
https://www.ncbi.nlm.nih.gov/pubmed/27844037
http://dx.doi.org/10.1212/NXI.0000000000000297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087255/
https://www.ncbi.nlm.nih.gov/pubmed/27844037
http://dx.doi.org/10.1212/NXI.0000000000000297

Ejemplares similares